NEW YORK, NY / ACCESSWIRE / March 2, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CymaBay Therapeutics, Inc. ("CymaBay" or "the Company") (NASDAQ:CBAY). Investors who purchased CymaBay securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/cbay.
The investigation concerns whether CymaBay and certain of its officers and/or directors have violated federal securities laws.
On January 29, 2020, CymbaBay announced in a letter that its President and CEO, that it had been "working to assess all potential ways to maximize value for our shareholders, including liquidation, sale, merger, asset acquisitions, and/or continuing development of our internal programs." Follwing this news, CymaBay stock dropped $0.21 per share, or over 11%, to close at $1.65 on January 30, 2020.
If you are aware of any facts relating to this investigation, or purchased CymaBay shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/cbay. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC